We read with interest the article by Klufas et al. [1] comparing gene expression profiling (GEP) and FISH/MLPA for chromosome 3 in a small cohort of uveal melanoma patients. The results from this single-center study confirm the presence of discordance between GEP and chromosome 3 testing, which has been reported previously [2] . However, the authors erroneously suggest that DNA testing (FISH or MLPA) is "more sensitive at detecting high risk for metastasis patients" [1] .
We wholeheartedly agree with the accompanying editorial, in which the authors state: "any technical advantage of each test can only be speculated because prognostic superiority of either test (GEP or MLPA) cannot be ascertained by this study as the prognostic prediction was not correlated with patient survival" [3] .
The GEP signature was designed with the goal of identifying patients at high risk for metastasis and not to identify chromosome 3 copy number changes, so these tests are measuring different, albeit related, biological properties. The GEP test measures expression of 12 discriminating genes on 7 chromosomes, including chromosome 3. Therefore, Class 1 and 2 GEPs are not surrogates for disomy and monosomy 3, respectively, and thus, some discordance between 2 tests measuring different endpoints is to be expected. The 15-16% discordance found between chromosome 3 and GEP assessment is consistent with reports by the Collaborative Ocular Oncology Group (COOG) [2] and others. To date, the COOG report is the only study that has reported survival data for discordant cases and showed that GEP was a more accurate predictor of clinical outcomes [2] .
The authors refer to GEP as an "inherently inaccurate test" [1] without providing any support for this assertion. The prognostic value of this test has been demonstrated in several single-and multi-center studies with consistent accuracy in identifying the great majority of patients who develop metastasis as Class 2. Here and previously [4] , the authors criticize GEP for producing a result in non-uveal melanoma tissue; however, GEP is not a diagnostic test and should not be used as such. It is important to clarify misinterpretations of GEP, particularly as the authors have previously
